Avraham Ben-Tzvi - 01 Oct 2025 Form 4 Insider Report for TITAN PHARMACEUTICALS INC (TTNP)

Reporting relationship: Director
Issuer ticker: TTNP
Reported as of: 01 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2025, 20:21:28 UTC
Prior SEC filing: 28 Feb 2025
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Avraham Ben-Tzvi

Key filing fact

Avraham Ben-Tzvi filed Form 4 for TITAN PHARMACEUTICALS INC (TTNP) on 08 Oct 2025.

Key facts

This page summarizes Avraham Ben-Tzvi's Form 4 filing for TITAN PHARMACEUTICALS INC (TTNP).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 Oct 2025, 20:21.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001944721 Primary reporting owner

Ben-Tzvi Avraham

Relationship: Director
Address: 44 ZAYT SHEMEN ST., FLAT 4, EFRAT, ISRAEL
Signature: /s/ Avraham Ben-Tzvi
Signature date: 08 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TTNP transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -3,313
Change %: -100%
Price
Shares after: 0
Date: 01 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TTNP transaction Derivative

Option to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -1,250
Change %: -100%
Price
Shares after: 0
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,250
Exercise price
Footnotes: F2

TTNP transaction Derivative

Option to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -5,000
Change %: -100%
Price
Shares after: 0
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").

Footnote F2

Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

Footnote F3

Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.